Advice on the use of Optowire (sterile, fibreoptic-based, disposable guide wire) for measuring fractional flow reserve (FFR) to aid local decision making
Advice on the use of AmnioSense (non-invasive diagnostic pad/liner) for unexplained vaginal wetness in pregnancy to aid local decision making
Summary of the evidence on antimicrobial prescribing of meropenem with vaborbactam (Vaborem) to inform local NHS planning and decision making
Advice on the use of Leukomed Sorbact for preventing surgical site infection (SSI) to aid local decision making
As a public body, NICE is required to follow civil service principles on communicating during the lead up to the general election.
We’ve temporarily withdrawn this medtech innovation briefing to correct factual errors in the text.
Chris Bird, Quality Standards Programme Manager, tells us how NICE developed the latest learning disability quality standards
Study will measure public’s preference for different health states
Advice on the use of superDimension Navigation System to help diagnostic sampling of peripheral lung lesions to aid local decision making
Advice on the use of MR-proADM test for use with clinical deterioration scores in cases of suspected infection to aid local decision making
An ovarian cancer treatment, designed to help maintain the effects of chemotherapy, has been approved by NICE for use in the Cancer Drugs Fund (CDF).
Draft guidance published today (3 October 2019) by NICE does not recommend atezolizumab (also called Tecentriq and made by Roche) for treating people with a type of breast cancer called triple A breast cancer that has spread to other parts of the body and who can’t have surgery to remove it.
NICE has said that a new drug for preventing migraine is not a cost effective use of NHS resources, in final draft guidance published today (26 September 2019).
Operations are set to start taking place in the NHS
Regularly monitoring women who are pregnant with twins or triplets, to spot any possible complications, can lead to better outcomes for mothers and their babies, as highlighted in NICE’s impact report.
Deborah Duval, the editor of Kidney Matters magazine, tells us how we can enjoy food even on a restricted renal diet
Consultation on priority areas open to stakeholders until mid October
Higher quality evidence would allow NICE to make recommendations on a range of therapies that could help people with tinnitus.
Heidi Livingstone, senior public involvement adviser within NICE's Public Involvement Programme, reflects on the partnership with CMAC
Advice on the use of Alpha-Stim AID for anxiety to aid local decision making
It is estimated that in the UK there are around 30 to 50 children living with the condition
Recruitment for the 2020 intake is open until 28 October 2019
Providing support after a suspected suicide can reduce this risk, especially when tailored to the person’s needs.
Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making
Advice on the use of UroShield for preventing catheter-associated urinary tract infections (CAUTI) to aid local decision making
Advice on the use of SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea to aid local decision making
It's estimated that 86 people would be eligible for treatment with voretigene neparvovec in England
Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making
KTT5 Asthma: medicines safety priorities Key points Inhaled corticosteroids (ICS) are
KTT9 Antimicrobial stewardship: prescribing antibiotics Key points Antimicrobial resistance
KTT12 Type 2 diabetes mellitus: medicines optimisation priorities Key points The NICE
KTT18 Multimorbidity and polypharmacy Key points Multimorbidity is associated with
KTT16 Anticoagulants, including direct-acting oral anticoagulants (DOACs) Key points
KTT3 Lipid-modifying drugs Key points The NICE guideline on cardiovascular disease:
KTT7 Antipsychotics in people living with dementia Key points The risks and limited
KTT14 Wound care products Key points A large number of wound dressings are available
KTT17 Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI Key points
KTT6 Hypnotics Key points The risks associated with hypnotics (including melatonin)
KTT21 Medicines optimisation in chronic pain Key points Controlling chronic pain can
KTT19 Psychotropic medicines in people with learning disabilities whose behaviour challenges Key points
KTT20 Safer insulin prescribing Key points Several new insulin products have been launched
KTT22 Chemotherapy dose standardisation Key points Chemotherapy dose standardisation
KTT24 Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide Key points
KTT23 Shared decision making Key points In the context of medicines optimisation, shared
NICE has today (23 August 2019) announced its intention to work with GW Pharma to address the issues highlighted by its independent appraisal committee in its evaluation of cannabidiol for treating 2 types of severe treatment-resistant epilepsy.
Chief executive has been at the helm of the institute since it was founded in April 1999
NICE has today (8 August 2019) published its draft recommendations on the use of cannabis-based medicinal products following a comprehensive evaluation of their clinical and cost-effectiveness.
Another new life-extending treatment for some people with lung cancer is to be made available on the Cancer Drugs Fund (CDF) following its approval by NICE in draft guidance published today (8 August 2019).
NICE has today (7 August 2019) published draft guidance recommending neratinib as an additional treatment for some people with early hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making